Skip to main content

Adjuvant hormonal therapy is recommended or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0 or Stage IB – Stage III hormone receptor positive breast cancer

CBE ID
0220
Endorsed
Endorsement Status
Endorsed
1.1 New or Maintenance
Maintenance
E&M Cycle
Fall 2019
Is Under Review
No
Next Planned Maintenance Review
Fall 2025
1.3 Measure Description

Percentage of female patients, age = 18 at diagnosis, who have their first diagnosis of cancer (epithelial malignancy), at AJCC T1cN0M0 or stage IB to IIIC, whose primary tumor is of the breast, and is progesterone or estrogen receptor positive with adjuvant hormonal therapy (recommended or administered) within 1 year (365 days) of diagnosis

    • 1.5 Measure Type
      Process
      1.7 Electronic Clinical Quality Measure (eCQM)
      No
      1.8 Level Of Analysis
      Facility
    • 1.14 Numerator

      Adjuvant hormonal therapy is administered within 1 year (365 days) of the date of diagnosis or it is recommended but not administered

    • 1.15 Denominator

      Include if all of the following characteristics are identified:
      Women
      Age = 18 at time of diagnosis
      Known or assumed to be first or only cancer diagnosis
      Epithelial malignancy only
      Invasive tumors
      Primary tumors of the breast
      AJCC T1cN0M0 or Stage IB – IIIC 
      Primary tumor is estrogen receptor positive or progesterone receptor positive
      All or part of 1st course of treatment performed at the reporting facility
      Known to be alive within 1 year (365 days) of date of diagnosis
      Surgical procedure of the primary site

    • Exclusions

      Exclude, if any of the following characteristics are identified:
      Men
      Under age 18 at time of diagnosis
      Second or subsequent cancer diagnosis
      Tumor not originating in the breast
      Non-epithelial malignancies, exclude malignant phyllodes tumors; 8940 - Mixed tumor, malignant, NOS; 8950 - Mullerian mixed tumor; 8980 - Carcinosarcoma; 8981 - Carcinosarcoma, embryonal
      Non-invasive tumors
      Stage 0, in-situ tumor
      Stage IV, metastatic tumor
      Primary tumor is estrogen receptor negative and progesterone receptor negative
      None of 1st course therapy performed at reporting facility
      Died within 1 year (365 days) of diagnosis,
      Patient enrolled in a clinical trial that directly impacts delivery of the standard of care
      No surgical procedure of the primary site
      Not AJCC T1cN0M0 or not AJCC stage IB-IIIC

    • 1.13a Data dictionary not attached
      No
    • Most Recent Endorsement Activity
      Endorsed Cancer Fall Cycle 2019
      Initial Endorsement
      Last Updated
    • Risk Adjustment
      No risk adjustment or risk stratification
      Risk adjustment approach
      Off
      Risk adjustment approach
      Off
      Conceptual model for risk adjustment
      Off
      Conceptual model for risk adjustment
      Off